The nation of Zimbabwe has rejected a major US healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's request for confidential information.
This rejection was revealed after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative later stated that the United States was seeking genetic material for scientific study and profit but was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged further talks to reach a agreement suitable to both sides so the nation's vital HIV programme can proceed.
Broader Implications
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court suspended a similar deal with the US after legal challenges were raised about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and responsibility.
Based on statements, Sixteen African countries have to date agreed to similar health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Put simply, our country would supply the basic resources for scientific discovery without any assurance that the final treatments would be available to our citizens should a future health crisis arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This framework is designed to ensure that when a nation contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome ongoing discussions with our US partners on how future co-operation might be arranged in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it acknowledged the official position, but recommended that talks must proceed considering a large portion of the nation's HIV programmes depended on external financing.
"In cases where technical issues exist, such as those relating to information security or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," the group added.
The halted deal highlights the ongoing challenges between receiving crucial foreign assistance and protecting a country's data in an ever more interconnected world.